Photodynamic therapy for localised prostatic cancer: light penetration in the human prostate gland
- PMID: 2299739
- DOI: 10.1016/s0022-5347(17)39973-1
Photodynamic therapy for localised prostatic cancer: light penetration in the human prostate gland
Abstract
We are investigating the feasibility of photodynamic therapy in the treatment of localised prostatic cancer. Of major importance in this form of treatment is the extent to which light penetrates the target organ; hence, our interest in the optical properties of the human prostate gland. We obtained three whole prostates from autopsies of patients who died of non-urological causes. Red light was launched interstitially and detector fibres measured light intensity as a function of distance from the delivery fibre end. The optical constants derived from the three prostates were almost identical and indicated that light was predominantly scattered rather than absorbed (mean absorption and scattering coefficients 0.07 +/- 0.02 mm.-1 and 0.86 +/- 0.05 mm.-1 respectively). In a comparison of the tissue penetration by four different wavelengths, 633 nm red light was found to be transmitted best. Light propagation in the heavily absorbing tissue of the human liver was 4.3 times poorer than in the prostate. Such a combination of low absorption and high scattering characteristics in prostatic tissue would enhance the effectiveness of PDT. The optical constants derived will enable "light treatment planning" in patients with prostatic cancer.
Similar articles
-
Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy.Photochem Photobiol. 2005 Jan-Feb;81(1):96-105. doi: 10.1562/2004-06-25-RA-216. Photochem Photobiol. 2005. PMID: 15535736 Free PMC article. Clinical Trial.
-
In situ comparison of 665 nm and 633 nm wavelength light penetration in the human prostate gland.Photochem Photobiol. 1995 Nov;62(5):882-6. doi: 10.1111/j.1751-1097.1995.tb09151.x. Photochem Photobiol. 1995. PMID: 8570727
-
In vivo laser light distribution in human prostatic carcinoma.J Urol. 1994 May;151(5):1411-5. doi: 10.1016/s0022-5347(17)35270-9. J Urol. 1994. PMID: 8158797
-
Laser dosimetry studies in the prostate.J Clin Laser Med Surg. 1998 Feb;16(1):9-12. doi: 10.1089/clm.1998.16.9. J Clin Laser Med Surg. 1998. PMID: 9728124 Review.
-
Photodynamic therapy for prostate cancer--an emerging approach for organ-confined disease.Lasers Surg Med. 2011 Sep;43(7):768-75. doi: 10.1002/lsm.21104. Lasers Surg Med. 2011. PMID: 22057504 Review.
Cited by
-
Photodynamic therapy: a new approach to prostate cancer.Curr Urol Rep. 2003 Jun;4(3):221-8. doi: 10.1007/s11934-003-0073-4. Curr Urol Rep. 2003. PMID: 12756086 Review.
-
Photodynamic therapy for prostate cancer--a review of current status and future promise.Nat Clin Pract Urol. 2009 Jan;6(1):18-30. doi: 10.1038/ncpuro1274. Nat Clin Pract Urol. 2009. PMID: 19132003 Review.
-
Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning.Lasers Med Sci. 2017 Aug;32(6):1301-1307. doi: 10.1007/s10103-017-2241-7. Epub 2017 Jun 1. Lasers Med Sci. 2017. PMID: 28569345 Clinical Trial.
-
Periodic health examination, 1991 update: 3. Secondary prevention of prostate cancer. Canadian Task Force on the Periodic Health Examination.CMAJ. 1991 Sep 1;145(5):413-28. CMAJ. 1991. PMID: 1878824 Free PMC article. Review. No abstract available.
-
Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy.J Photochem Photobiol B. 2005 Jun 1;79(3):231-41. doi: 10.1016/j.jphotobiol.2004.09.013. Epub 2004 Dec 2. J Photochem Photobiol B. 2005. PMID: 15896650 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical